Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials

Author:

Mizusawa Junki12ORCID,Sato Hioryuki3,Rubinstein Larry V.4,Fujiwara Takeo2,Yonemori Kan5,Hirakawa Akihiro3

Affiliation:

1. Biostatistics Section, Clinical Research Support Office, National Cancer Center Hospital/Biostatistics Division, Center for Research Administration & Support National Cancer Center Tokyo Japan

2. Department of Global Health Promotion Tokyo Medical and Dental University Tokyo Japan

3. Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University Tokyo Japan

4. Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute National Institute of Health Rockville Maryland USA

5. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

Abstract

AbstractBackgroundRacial differences have been reported in toxicity outcomes for anticancer drug treatments. However, these observations were often from studies with small sample sizes, and many only reported the maximum grade of toxicity and no longitudinal information. This current analysis aims to investigate racial differences in longitudinal toxicities using a large‐scale clinical trials database.MethodsEarly‐phase clinical trials sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute, USA, that evaluated cytotoxic drugs and molecularly targeted agents between March 2000 and December 2012 were studied. Race was categorized as White, Black or African‐American, and Asian. Each toxicity's grade prevalence, mean grade at each cycle, and time to develop grade 2 or higher toxicity was evaluated.ResultsIn total, 25,442 patients from 697 trials were included in this study. The number of patients categorized as White, Black, and Asian designations was 22,756 (89%), 1874 (7%), and 812 (3%), respectively. Notable findings include the rate of any grade of diarrhea in Black people was 26% and 21% lower than that of White and Asian people. The median time to the first grade 2 or higher event was 6 cycles in White people, 8 in Black people, and 6 in Asian people. The rate of any grade hyperglycemia was significantly higher in Asian people.ConclusionsAlthough we identified several racial differences in longitudinal toxicities, most were of generally lower grade. Further study is needed to clarify the cause of racial differences in treatment‐associated toxicities.

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference53 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. SEER*Explorer.An interactive website for seer cancer statistics. Surveillance research program National Cancer Institute.2023.https://seer.cancer.gov/statistics‐network/explorer/. Data source(s): Seer incidence data November 2022 submission (1975–2020) seer 22 registries

3. Longitudinal health utility and symptom‐toxicity trajectories in patients with head and neck cancers

4. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis

5. Contrasts in Survival of Black and White Cancer Patients, 1960–73

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3